To examine whether infants exposed to tocolytics are at increased risk for selected adverse clinical and hospitalization outcomes.
INTRODUCTION
Preterm birth resulting from preterm labor (PTL) is the most common cause of perinatal morbidity and mortality. Thus, its prevention and treatment are major concerns in obstetric care. However, the use of tocolytics in the management of PTL has not been proven to prevent neonatal morbidity and mortality, and may have potential harmful effects on infants. [1] [2] [3] [4] This lack of consensus about the efficacy and safety of tocolysis must be evaluated within the broader context that survival of infants delivered at tertiary care centers has improved annually, particularly for the subset of very premature infants (25 to 32 weeks gestational age). [5] [6] [7] [8] The purpose of this study is two-fold: firstly, to examine whether maternal exposure to tocolytics is associated with subsequent increases in duration of infant hospitalization, transfer to another facility, cost as a result of neonatal complications, and infant rehospitalization within the first year of life compared to infants whose mothers had PTL and were not treated with tocolysis; and secondly, to examine morbidity and mortality among infants of mothers with PTL who did and did not receive tocolysis. To address these questions, in the state of Washington, between 1989 and 2001, we conducted a population-based cohort study of mothers with singleton deliveries who experienced PTL.
METHODS
Procedures for this study were approved by the Institutional Review Boards of the Washington State Department of Health (WSDOH) and the University of Washington. We conducted a populationbased cohort study using the Comprehensive Hospital Abstract Reporting System (CHARS), the Birth Events Records Database (BERD), and birth certificate/death certificate data from Washington State for the years 1989 to 2001. These linked databases are created annually by the WSDOH and contain hospital discharge data for all hospitalizations to nonmilitary facilities in the state. The exposed cohort included all women with singleton deliveries who received tocolysis for PTL as noted by the marked checkbox on the birth certificate (N ¼ 28,264). An unexposed comparison group (N ¼ 51,415) included all women for whom PTL was indicated as a condition at their birth hospitalization based on ICD-9 codes (644.0 to 644.4), but who did not receive tocolytics. Linkage of birth certificates to hospital discharge data for the previous year also identified women who experienced PTL prior to their delivery hospitalization; these were included in the comparison group as well.
Women contraindicated for tocolysis according to the current standard of care and women noted to have additional medical conditions that could have been treated with medications misclassified as tocolytics were excluded. Exclusion criteria included: hypertension/eclampsia/pre-eclampsia (ICD-9 642), excessive maternal bleeding/abrupted placenta/placenta previa (ICD-9 762.0, 762.1, 762.2), premature rupture of membranes/ incompetent cervix (ICD-9 761), fetal distress (ICD-9 656.3, 768.3, 768.4), and maternal infection/chorioamnionitis (ICD-9 762.7). In addition, women whose infants were diagnosed with congenital abnormalities (ICD-9 740 to 759) were excluded, because these conditions may place them in a unique category with respect to both indications for tocolysis and neonatal outcome. Final analysis was performed on 18,620 women who received tocolysis and 34,329 women who did not receive tocolysis.
Infant clinical outcomes of interest were complications such as noncongenital serious bacterial infection (ICD-9 038, ICD-9 041.0 to 041.9, ICD-9 320), cerebral hemorrhage (ICD-9 772.1, 767.0), necrotizing enterocolitis (NEC) (ICD-9 777.5), respiratory distress (indicated on the birth certificate by checkbox format, or on the hospital discharge record by ICD-9 769, 770.9, 770.7, 770.8), and the need for endotracheal intubation (ICD-9 procedure code 9604). These conditions were recognized as contributing to prolonged hospital stay, increased hospital costs, and overall infant morbidity/ mortality. A 5-minute APGAR score of less than 7 was considered predictive of poor infant outcome. 9, 10 The final outcome examined was infant death at less than a year of age.
The hospitalization outcomes evaluated included infant transfer to another facility after delivery, infant delivery hospitalization greater than 48 hours, infant rehospitalization within the first year of life, and total infant cost of the birth hospitalization. Infant transfer suggests a need for increased level of care. Infant hospitalization for more than 48 hours was chosen as a primary outcome measure based on the current American Academy of Pediatrics' recommendations that well-appearing, term (Z37 weeks gestational age) infants be observed 24 to 48 hours before hospital discharge. 11 The median infant birth hospitalization cost ($1396.00, calculated from BERD) for all infants born in Washington State from 1989 to 2001 was used as a reference to evaluate infant birth hospitalization cost.
Relative risks for the infant clinical and hospitalization outcomes were estimated using multivariate logistic regression (Statistical Analysis Software 6.09). Gestational age at delivery as a continuous measure was used to adjust for the potential confounding effects of gestational age. While gestational length based on prenatal ultrasound evaluation can be considered a more accurate estimation of gestational age, it was not used because a large portion of these data were missing from the birth certificate database. Adjustment for year of birth was necessary to account for time-dependent trends in the treatment of PTL, as well as changes that have occurred in clinical practices, cost, and infant mortality rates from 1989 until 2001. Other potential confounding factors we investigated included: birth weight (500 to 1499, 1500 to 2499, and Z2500 g), maternal age (<20, 20 to 34, and Z35 years), race, marital status, smoking, parity, prior preterm delivery, level of prenatal care (as measured by the Kotelchuck index 12 ), mode of delivery, and complications during or related to pregnancy (single checkbox on the birth certificate indicating ''any complications during or related to pregnancy''). To explore potential interaction between infant gestational age and exposure to tocolysis, risks for adverse infant clinical and hospitalization outcomes were stratified by clinically relevant gestational age categories (23 to 27, 28 to 36, and 37 þ weeks).
For the subgroup of infants readmitted to the hospital within the first year of life (N ¼ 6341), we describe conditions for which they were admitted. Those with a potential biological relationship to clinical outcomes previously noted (respiratory distress, sepsis/ infection, intubation, intraventricular hemorrhage, and NEC) were identified. Readmission diagnoses were broadly grouped into five categories: upper airway pathology, lower airway pathology, neurologic sequela, serious bacterial infection, and those conditions related to difficulty feeding/gastrointestinal tract. The possibility that a small subgroup of infants with chronic conditions might contribute a bulk of the readmissions was accounted for by analyzing the total group of readmitted infants, as well as those with only one readmission within the first year of life.
RESULTS
Demographic characteristics and past obstetric history of women with PTL who were and were not treated with tocolytics were similar with respect to age, smoking, marital status, parity, and history of prior preterm delivery (Table 1) . However, with regard to race, white women were less likely to be exposed to tocolytics (68% exposed vs 73% unexposed), and black and Asian women were more likely to be exposed (8% exposed vs 5% unexposed; 10% exposed vs 6% unexposed, respectively). Comparing details of these two groups' clinical experience during pregnancy and delivery, they were similar with respect to time from diagnosis of PTL until delivery, prenatal care received, source for birth admission, birth hospitalization length of stay, and discharge status ( Table 2) . Birth certificate checkbox indicated that 43% of the total sample had a history of complications during or related to pregnancy, and among these, 47% had received tocolytics while 53% had not. A greater percentage of women who received tocolysis were delivered by Cesarian section among both the total sample (21 vs 18%), and those without prior births (20 vs 14%).
We observed discrepancies in infant characteristics between the two groups, most notably gestational age and birth weight (Table 1 ). In the tocolytic group, 78% were delivered at Z37 weeks gestational age compared to 46% of the infants born to mothers not treated with tocolytics. The majority of infants born to untreated mothers were between 28 and 36 weeks gestational age (52%). Similarly, we found that 87% of infants born to mothers in the tocolytic group weighed Z2500 g at birth compared to 71% in the nontocolyzed group.
Risk estimates were unaffected by multivariate regression for race, smoking status, maternal age, marital status, prenatal care, parity, prior preterm delivery, and complications during or related to pregnancy. A greater percentage of women in the tocolysis group delivered by Cesarian section, which could impact infant length of stay and infant birth hospitalization costs; therefore, we adjusted for mode of delivery in risk estimations of these two outcomes.
Infants of women with PTL who received tocolytics were at increased risk of rehospitalization within the first year of life (RR ¼ 1.2, 95% CI ¼ 1.1 to 1.3), transfer to another facility (RR ¼ 1.5, 95% CI ¼ 1.3 to 1.8), and hospital stay of >2 days (RR ¼ 1.4, 95% CI ¼ 1.3 to 1.4). Among the exposed infants, the costs of infant birth hospitalization were more likely to be above the overall median birth hospitalization costs (RR ¼ 2.3, 95% CI ¼ 2.2 to 2.4) ( Table 3) . Tocolysis exposure did not have a significant impact on infant death (RR ¼ 1.1, 95% CI ¼ 0.9 to 1.4), 5-minute APGAR score (RR ¼ 0.9, 95% CI ¼ 0.8 to 1.0), or intraventricular hemorrhage (RR ¼ 1.0, 95% CI ¼ 0.8 to 1.3). However, we observed a significant increase in risk for infant respiratory distress associated with tocolytic exposure (RR ¼ 1.5, 95% CI ¼ 1.4 to 1.6), need for endotracheal intubation (RR ¼ 1.3, 95% CI ¼ 1.2 to 1.5), and risk for neonatal sepsis/serious bacterial infection (RR ¼ 1.6, 95% CI ¼ 1.4 to 1.8) ( Table 3) .
The risk of adverse hospitalization and clinical outcomes associated with exposure to tocolysis varied by gestational age at delivery (Table 4) . Infants delivered at 28 to 36 weeks gestational age, whose mothers were treated with tocolysis, showed a modest reduction in the risk of depressed APGAR score (RR ¼ 0.7, 95% CI ¼ 0.6 to 0.8) and intraventricular hemorrhage (RR ¼ 0.6 95% CI ¼ 0.4 to 0.8). Otherwise, for these infants no significant protective effects were conferred by treatment with tocolytics. Among infants born very premature (23 to 27 weeks gestational age) and those born at term (37 þ weeks gestational age), we did not observe any protective effects of tocolytic exposure; these infants had significantly increased risk for transfer to another facility, increased costs, respiratory distress, intubation, and sepsis. In the subset of infants requiring readmission within the first year of life, the majority of readmission diagnoses fell into the ''lower airway'' diagnostic category. Diagnoses were similar between those with a history of in utero tocolytic exposure and those without (Table 5) .
DISCUSSION
Treatment of PTL with tocolytics has not been firmly proven to improve neonatal outcome, and questions remain as to their association with infant morbidity and mortality. The results of this study suggest that significant benefits were not conferred to infants whose mothers were treated with tocolytics, and these infants appeared to have relatively poorer hospitalization and clinical outcomes. After controlling for gestational age at delivery and year of birth, we observed increased risks for infant respiratory distress, endotracheal intubation, and serious bacterial infection. These outcomes may account for increased length of stay, increased transfer, and increased cost that we observed in cases of infants born to mothers exposed to tocolysis. The risk of rehospitalization associated with maternal tocolytic treatment was significantly increased; however, descriptive analysis of the readmission diagnoses did not indicate unique pathology that could be directly attributed to tocolytic exposure. The increased risk of respiratory distress, endotracheal intubation, serious bacterial infection, and adverse hospitalization outcomes appeared to be modified by the infants' gestational age at delivery. The youngest and oldest infants suffered the greatest negative impact, while those delivered between 28 and 36 weeks gestational age failed to show dramatic benefit from exposure. These results however, only take into account the infant's gestational age at delivery. We were unable to adequately adjust for the gestational age at the start of tocolysis; therefore, it is difficult to make a definitive comment on how the timing of fetal exposure to tocolytic agents interacts to affect neonatal outcome. Tocolytics are a diverse group of medications administered to mothers with PTL in order to delay delivery. They include magnesium sulfate, beta-adrenergic agents (terbutaline), prostaglandin synthetase inhibitors (indomethacin), and calciumchannel blockers (nifedipine). Consensus is lacking among obstetricians as to which tocolytic is the most effective for treatment of PTL, and safest with regard to both the mother and infant. Currently, the most commonly used medications for tocolysis are terbutaline and magnesium sulfate. 5, [13] [14] [15] [16] Therefore, it is likely that most of the women in our study were treated with one or both of these agents.
Since 1984, a limited number of randomized controlled trials specifically comment on infant mortality associated with magnesium use. The Magnesium and Neurologic Endpoints trial was a randomized controlled trial evaluating treatment of PTL with magnesium, and subsequent neonatal mortality and cerebral palsy. The trial was suspended after 15 months of enrollment because of excess pediatric mortality among those exposed to magnesium sulfate compared to those assigned to other tocolytics (AR ¼ 15.2, 95% CI ¼ 4.8 to 25.6). 5, 6, 17 A random-effects model meta-analysis combining data from this study with one by Cox et al. 18 showed a statistically significant association between tocolytic magnesium and total pediatric death (AR ¼ 10.7, 95% CI ¼ 3.9 to 17.6). 2 In addition to these studies, others have demonstrated an association of magnesium exposure with adverse infant outcome. 1, 4, [19] [20] [21] Most convincing was a Cochrane review by Crowther et al. 22 of 23 trails assessing the safety and efficacy of magnesium tocolysis. They concluded the magnesium sulfate is ineffective at delaying birth or preventing preterm birth, and infant exposure was associated with an increased risk of mortality (RR 2.8, 95% CI 1.2 to 6.6, seven trails, 727 infants). The absence of benefit to the neonate has also been true of studies looking at the use of terbutaline alone, or as an adjunct to magnesium. 23 The fact that maternal treatment with tocolytics directly exposes the fetus to the effects of these medications as they cross the placenta helps explain a potential biologic mechanism for our observed outcomes. In infants whose mothers were treated with magnesium sulfate, significantly elevated levels of magnesium have been measured in the infant's cord blood at delivery. 17 Hypermagnesemia is a well-known cause of neonatal lethargy, hypotonia, and respiratory depression. 5 This diminished respiratory drive could explain the increased risk for respiratory distress and need for endotracheal intubation seen in the tocolytic-exposed infants in our study. Although we did not assess fetal lung maturity and treatment with prenatal steroids, the majority of infants exposed to tocolysis were delivered at term and adjustment for gestational age did not diminish the risk in the exposed infants.
The interactions that may occur between the developing fetal immune system and tocolytic agents are poorly understood. Therefore, it is difficult to postulate a direct biological mechanism to explain the observed association between serious bacterial infection and exposure to tocolysis. However, infants exposed to tocolysis were more likely to be intubated and had significantly longer hospital stays, both of which would put them at risk for acquiring iatrogenic infection. Many aspects of the study design minimized the potential for a biased risk estimate. Maternal infection as an etiology for PTL with reverse causation explaining the association between tocolysis and neonatal infection was eliminated by initial exclusions and coding decisions. Women with prolonged rupture of membranes or infection/chorioamnionitis were excluded from the study sample. In addition, congenitally acquired infections were not included in the sepsis/infection outcome measure. Further support for a true association between tocolysis and infant infection lies in the fact that a higher proportion of tocolytic-exposed infants were delivered by Cesarian section, theoretically decreasing their risk for infection by eliminating the potential for acquiring infection during passage through the birth canal. An increased risk for sepsis associated with tocolysis was also observed in a retrospective study of 240 infants by Ojala et al. 24 which evaluated the use of indomethasin for the treatment of PTL. We carefully considered the possibility that women who received tocolysis had a more complicated prenatal course, and this, not the direct effects of these medications, was responsible for a ''sicker'' infant at delivery. It is impossible to make a definitive comment on why one woman was treated with tocolysis and the other was not, and how these unaccounted for characteristics might have affected neonatal outcome. Differences between the two groups of women that potentially explain the observed infant outcomes were evaluated. Women with eclampsia, pre-eclampsia, maternal infection/chorioamnionitis, and fetal distress were excluded, thus removing these factors as a cause for the results. The obstetric characteristics and pregnancy experiences for the two groups of women were very similar. In fact, a greater percentage of women noted to have complications during or related to pregnancy were unexposed mothers, and adjustment for this factor did not alter risk estimates. Women who received tocolysis were more likely to have delivered by Cesarian section, which may be interpreted as an at-risk mother or infant. However, implications for adverse clinical outcomes and poor hospitalization outcomes were not reflected after adjustment for mode of delivery was made. In addition, important predictors for neonatal complications, young gestational age at delivery and low birth weight, were actually lower in the group of infants exposed to tocoloysis, theoretically giving this group a comparative advantage against developing complications associated with prematurity.
Certain limitations of this study with regard to exposure status must be addressed. The women's tocolytic exposure was identified through the Washington State birth certificate database. It records maternal treatment with tocolysis as a dichotomous variable. No information was available to identify specifically which tocolytic was used, the dose, the duration of exposure, or the exact timing of exposure. Also, medical records were not examined to confirm a diagnosis of PTL; we assumed that all women who received tocolytics did so because they had PTL. Potential misclassification by this assumption was minimized by the fact that the only indication for tocolysis is the treatment of PTL, and medical conditions that could have been treated with the same agents and misinterpreted as being used for tocolysis were excluded.
Tocolytic treatment has been demonstrated to be of benefit to the neonate when the time gained is used for administration of prenatal steroids or transfer to a high-risk facility. Yet this study and others raise concerns regarding the potential for elevated risk of adverse outcomes among infants whose mothers are treated with tocolytics. 7, 23 In a medical system where great strides have been made in decreasing morbidity and mortality among infants born at younger gestational ages, should the role tocolytics play in treating PTL and prolonging gestation be re-evaluated? Randomized controlled studies examining the association between tocolytic type, dose, and timing of exposure and direct infant benefits and risks would contribute to our understanding of the broader impact of tocolytic agents.
